Drug details

Nuwiq (antihemophilic factor recombinant intravenous infusion)

type of Hemostatics, Coagulation Factors

Nuwiq, Antihemophilic Factor (Recombinant) is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Nuwiq is not indicated for the treatment of von Willebrand Disease.

This drug may have the following side effects:

•  headache
•  dry mouth
• back pain
• weakness
• injection site inflammation or pain
• non-neutralizing anti-Factor VIII antibody formation
• spinning sensation (vertigo), and

The following drugs are related to Nuwiq, either as a replacement or used together:

• Advate ([antihemophilic factor (recombinant), plasma/albumin-free method] for intravenous injection)
• Alprolix ([coagulation factor ix (recombinant), fc fusion protein], lyophilized powder for solution for intravenous injection)
• Altuviiio (antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl)
• Monoclate-P (antihemophilic factor)
• Bebulin VH (factor ix complex intravenous administration)
• BeneFIX (coagulation factor ix recombinant for injection)
• Novoseven (coagulation factor viia (recombinant))
• Sevenfact (coagulation factor viia (recombinant)-jncw for injection)
• Esperoct ([antihemophilic factor (recombinant), glycopegylated-exei] injection)
• Konyne (factor ix complex)
• Profilnine (factor ix complex intravenous administration)
• Roctavian (valoctocogene roxaparvovec-rvox suspension)